Security key
816212302
Cartesian Therapeutics, Inc. - Common Stock, $0.0001 par value per share (RNAC)
CUSIP: 816212302
Q4 2024 13F Holders as of 31 Dec 2024
- Security type / class
- Equity / Common Stock, $0.0001 par value per share
- Total 13F shares
- 6,665,799
- Total 13F value
- $119,478,509
- Share change
- -204,176
- SEC-reported price per share
- $17.91
- Number of holders
- 64
- Value change
- -$2,692,613
- Number of buys
- 37
- Number of sells
- 18
- Shares outstanding
- 30,963,583
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2024
Institutions
64
Top holders
10
RNAC full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2026
Cartesian Therapeutics, Inc. SEC filings
Cartesian Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 816212302
Recent filing periods:
Ownership snapshot
Top reported holders of RNAC - Cartesian Therapeutics, Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
FMR LLC
Disclosed value leader
FMR LLC
Comparable rows
15/15
Latest evidence
30 Sep 2024
13F
Lead comparable stake: 9.2%
Showing 1-6 of 15 holder rows.
Quick read
FMR LLC leads the comparable SEC ownership view at 9.2%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens FMR LLC's linked filing trail.
Comparable ownership
Top 5
FMR LLC
9.2%
MPM BioImpact LLC
2%
Siren, L.L.C.
1.8%
BlackRock, Inc.
1.4%
CITADEL ADVISORS LLC
1.2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| FMR LLC |
13F
Company
|
9.2%
|
$45,971,500
2,851,830 shares
|
— | 30 Sep 2024 |
| MPM BioImpact LLC |
13F
Company
|
2%
|
$10,146,299
629,423 shares
|
— | 30 Sep 2024 |
| Siren, L.L.C. |
13F
Individual
|
1.8%
|
$9,224,444
572,236 shares
|
— | 30 Sep 2024 |
| BlackRock, Inc. |
13F
Company
|
1.4%
|
$6,826,277
423,466 shares
|
— | 30 Sep 2024 |
| CITADEL ADVISORS LLC |
13F
Company
|
1.2%
|
$5,759,450
375,767 shares
|
— | 30 Sep 2024 |
| JPMORGAN CHASE & CO |
13F
Company
|
1%
|
$4,981,371
309,018 shares
|
— | 30 Sep 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
64
Shares
6,665,799
Rows available
64
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2024 vs Q3 2024 Across Filers
Q3 2024 holders
61
Q4 2024 holders
64
Holder diff
3
| Investor | Q3 2024 Shares | Q4 2024 Shares | Share Diff | Share Chg % | Q3 2024 value | Q4 2024 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend